van Loevezijn, Arnold; Venhorst, Jennifer; Iwema Bakker, Wouter I.; de Korte, Cor G.; de Looff, Wouter; Verhoog, Stefan; van Wees, Jan-Willem; van Hoeve, Martijn; van de Woestijne, Rob P.; van der Neut, Martina A. W.; Borst, Alice J. M.; van Dongen, Maria J. P.; de Bruin, Natasja M. W. J.; Keizer, Hiskias G.; Kruse, Chris G. published the artcile< N'-(Arylsulfonyl)pyrazoline-1-carboxamidines as Novel, Neutral 5-Hydroxytryptamine 6 Receptor (5-HT6R) Antagonists with Unique Structural Features>, Recommanded Product: 3-Fluorobenzenesulfonamide, the main research area is arylsulfonylpyrazolinecarboxamidine hydroxytryptamine 6 receptor antagonist.
The 5-HT6 receptor (5-HT6R) has been in the spotlight for several years regarding CNS-related diseases. We set out to discover novel, neutral 5-HT6R antagonists to improve off-target selectivity compared to basic amine-containing scaffolds dominating the field. High-throughput screening identified the N’-(sulfonyl)pyrazoline-1-carboxamidine scaffold as a promising neutral core for starting hit-to-lead. Medicinal chem., mol. modeling, small mol. NMR and X-ray crystallog. were subsequently applied to optimize the leads into antagonists displaying high 5-HT6R affinity with optimal off-target selectivity. Unique structural features include a pseudoarom. system and an internal hydrogen bond freezing the bioactive conformation. While physicochem. properties and CNS availability were generally favorable, significant efforts had to be made to improve metabolic stability. The optimized structure 42 (I) is an extremely selective, hERG-free, high-affinity 5-HT6R antagonist showing good human in vitro metabolic stability. Rat pharmacokinetic data were sufficiently good to enable further in vivo profiling.
Journal of Medicinal Chemistry published new progress about 5-HT antagonists (5-HT6). 1524-40-9 belongs to class amides-buliding-blocks, and the molecular formula is C6H6FNO2S, Recommanded Product: 3-Fluorobenzenesulfonamide.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics